Status:
COMPLETED
Real-life Efficacy of Insulia® Tool in Patients Living with Type 2 Diabetes Treated with Basal Insulin Therapy As Part of a National Telemedicine Program (ETAPES)
Lead Sponsor:
Centre Hospitalier Sud Francilien
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study was to evaluate the INSULIA digital tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentat...
Detailed Description
Basal insulin titration in people with type 2 diabetes is of major importance to obtain the optimal dose to regulate fasting blood glucose without hypoglycemia. Significant inertia in treatment optim...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old.
- Patients with type 2 diabetes.
- Initiation or adjustment of basal insulin.
- Prescription of Insulia® for more than 6 months (between august 2018 and june 2021)
- Informed patient not opposed to the research
Exclusion
- Patient opposed to the research
Key Trial Info
Start Date :
November 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 2 2022
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT05331339
Start Date
November 2 2022
End Date
December 2 2022
Last Update
November 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France, 91106